AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18639296 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 37
Study 18639296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 17040006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (4.5, 6.0, or 9.0 g per day)
Number of subjects: 285
Study 17040006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 14690184 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site QCA analysis
Number of subjects: 116
Study 14690184 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory QCA analysis
Number of subjects: 116
Study 10627097 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported drinking at treatment admission
Number of subjects: 1726
Study 10627097 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported drinking at 15-month follow-up
Number of subjects: 1726
Study 10627097 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood chemistry values (liver function tests) at treatment admission
Number of subjects: 1726
Study 10627097 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood chemistry values (liver function tests) at 15-month follow-up
Number of subjects: 1726
Study 10627097 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancies in self-report vs. biochemical measures
Number of subjects: 1726
Study 9002097 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized recall letters mailed to parents (n=153)
Number of subjects: 289
Study 9002097 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=136)
Number of subjects: 289
Study 9002097 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected recall letter policy for regional population
Number of subjects: 289
Study 7957001 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre reducing diet for 6 months
Number of subjects: 16
Study 7957001 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-dieting)
Number of subjects: 16
Study 3592329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chlorpromazine (CPZ) 1 mg/kg
Number of subjects: 36
Study 3592329 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study 3592329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chlorpromazine (CPZ)
Number of subjects: 36
Study 28980220 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Training (MT)
Number of subjects: 45
Study 28980220 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Weight Training (FWT)
Number of subjects: 45
Study 28980220 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 45
Study 26954409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU)
Number of subjects: 413
Study 26954409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 25460343 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-Fit group
Number of subjects: 128
Study 25460343 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitative care group
Number of subjects: 128
Study 23183252 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family based intervention
Number of subjects: 96
Study 23183252 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 96
Study 21218270 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace ergonomic improvements (Intervention group, N=89)
Number of subjects: 177
Study 18344738 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX-00023 (80 mg/d)
Number of subjects: 311
Study 18344738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 16797903 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training plus vitamin D 400 IU plus 800 mg of calcium per day
Number of subjects: 96
Study 16797903 — intervention group
Group type: COMPARATOR
Intervention: Resistance training plus calcium alone
Number of subjects: 96
Study 16797903 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-trained subjects supplemented with vitamin D
Number of subjects: 96
Study 16797903 — intervention group
Group type: COMPARATOR
Intervention: Non-trained subjects without vitamin D supplementation
Number of subjects: 96
Study 14557356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived progenitor cells (BMCs) or circulating progenitor cells (CPCs) infused into the infarct artery 4.7±1.7 days after AMI
Number of subjects: 28
Study 11094584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (T1)
Number of subjects: 29
Study 11094584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg (T2)
Number of subjects: 29
Study 11094584 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 29
Study 8930424 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 20 mg
Number of subjects: 736
Study 8930424 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg
Number of subjects: 736
Study 8930424 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg
Number of subjects: 736
Study 8930424 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 320 mg
Number of subjects: 736
Study 8930424 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 736
Study 8332965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (2 x 250 mg daily) from the second preoperative day until the seventh postoperative day
Number of subjects: 46
Study 8332965 — intervention group
Group type: COMPARATOR
Intervention: Placebo until the day of surgery and further acenocoumarol post-operatively
Number of subjects: 46
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 18
Study 3771472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg + Isoproterenol
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg + Isoproterenol
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg + Isoproterenol
Number of subjects: 18
Study 3771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg + Isoproterenol
Number of subjects: 18
Study 29506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 28.8 μg
Number of subjects: 0
Study 29506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 14.4 μg
Number of subjects: 0
Study 29506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 7.2 μg
Number of subjects: 0
Study 29506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI 3.6 μg
Number of subjects: 0
Study 29506504 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 0
Study 29506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium MDI 34 μg
Number of subjects: 0
Study 27255474 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5mg daily for 12 months)
Number of subjects: 355
Study 27255474 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplemented)
Number of subjects: 355
Study 25022762 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100
Study 25022762 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood injection
Number of subjects: 100
Study 25022762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needle tendon fenestration
Number of subjects: 100
Study 25022762 — intervention group
Group type: COMPARATOR
Intervention: Sham injection with physical therapy alone
Number of subjects: 100
Study 22886853 — intervention group
Group type: EXPERIMENTAL
Intervention: Low demand, high basal infusion (LDHI) strategy
Number of subjects: 0
Study 22886853 — intervention group
Group type: COMPARATOR
Intervention: High demand, low basal infusion (HDLI) strategy
Number of subjects: 0
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: log-transformed sum of triceps, biceps, subscapular and supra-iliac skinfolds (logSF4)
Number of subjects: 372
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: log-transformed sum of triceps and subscapular skinfolds (logSF2)
Number of subjects: 372
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: log-transformed triceps skinfold (logTSF)
Number of subjects: 372
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: log-transformed triceps skinfold (logTSF) combined with waist circumference
Number of subjects: 372
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 372
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 372
Study 20619073 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI combined with waist circumference
Number of subjects: 372
Study 18218746 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroking on the ventral part of the neck
Number of subjects: 60
Study 18218746 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroking on the withers
Number of subjects: 60
Study 18218746 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroking on the lateral side of the chest
Number of subjects: 60
Study 18218746 — intervention group
Group type: COMPARATOR
Intervention: Simple human presence (control)
Number of subjects: 60
Study 16167447 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 6
Study 16167447 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 6
Study 16167447 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study 12664016 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 0
Study 12664016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10802492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (INO) 20 ppm
Number of subjects: 235
Study 10802492 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen (control)
Number of subjects: 235
Study 9252000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulative physiotherapy treatment
Number of subjects: 15
Study 9252000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9252000 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 1504055 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) administered as a 1- or 2-hour i.v. infusion, with doses of 12 x 10(6) IU/m2, 18 x 10(6) IU/m2, and 24 x 10(6) IU/m2, given every Monday/Wednesday/Friday for 3 weeks
Number of subjects: 11
Study 6320226 — intervention group
Group type: EXPERIMENTAL
Intervention: delta 9‐tetrahydrocannabinol (THC) 17.5 mg orally
Number of subjects: 23
Study 6320226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 2 mg orally
Number of subjects: 23
Study 6320226 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g marihuana cigarette containing 1.83% THC, smoked
Number of subjects: 23
Study 6320226 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 23
Study 6320226 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 23
Study 31509674 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 group (fish-oil capsules containing 900 mg of n-3 long-chain polyunsaturated fatty acids)
Number of subjects: 5517
Study 31509674 — intervention group
Group type: COMPARATOR
Intervention: Control group (vegetable-oil capsules containing trace n-3 long-chain polyunsaturated fatty acids)
Number of subjects: 5517
Study 31509674 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 group
Number of subjects: 5517
Study 29038282 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% daily dosing under directly observed therapy (DOT)
Number of subjects: 48
Study 29038282 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% daily dosing under directly observed therapy (DOT)
Number of subjects: 48
Study 29038282 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% daily dosing under directly observed therapy (DOT)
Number of subjects: 48
Study 29038282 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosing regimens
Number of subjects: 48
Study 29038282 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TFV-DP levels between sexes
Number of subjects: 48
Study 27519769 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20 mg/day) for 12 weeks
Number of subjects: 15
Study 27519769 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (30 mg/kg/day, orally) for 7 days
Number of subjects: 15
Study 23455576 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 258
Study 23455576 — intervention group
Group type: EXPERIMENTAL
Intervention: ART restorations using high-viscosity glass ionomer
Number of subjects: 258
Study 23238507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol infusion 1-3 mg per hour
Number of subjects: 165
Study 23238507 — intervention group
Group type: COMPARATOR
Intervention: Biatrial pacing and oral metoprolol (50-150 mg daily for 72 hours)
Number of subjects: 165
Study 23238507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol infusion
Number of subjects: 165
Study 23238507 — intervention group
Group type: COMPARATOR
Intervention: Biatrial pacing and oral metoprolol
Number of subjects: 165
Study 20489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 20489805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18721511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 640
Study 18721511 — intervention group
Group type: COMPARATOR
Intervention: Moderate statin therapy
Number of subjects: 640
Study 18721511 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with previous CABG
Number of subjects: 640
Study 15793459 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid application (initially at home for 2 weeks, followed by higher concentration in-office weekly for six applications)
Number of subjects: 30
Study 15793459 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin product (topical application at home daily for 3 months)
Number of subjects: 30
Study 15793459 — intervention group
Group type: COMPARATOR
Intervention: Cream base (placebo) for 3 months
Number of subjects: 30
Study 12356207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 10624760 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal incremental cycle ergometer test
Number of subjects: 24
Study 10624760 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing frequency
Number of subjects: 24
Study 10624760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume
Number of subjects: 24
Study 10624760 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal partial pressure of carbon dioxide (PET,CO2)
Number of subjects: 24
Study 10624760 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between PET,CO2 and respiratory frequency during recovery
Number of subjects: 24
Study 10624760 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory complaints and paresthesias
Number of subjects: 24
Study 7547654 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms epinephrine
Number of subjects: 30
Study 7547654 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms epinephrine
Number of subjects: 30
Study 7547654 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine plain
Number of subjects: 30
Study 7547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 10 micrograms epinephrine
Number of subjects: 30
Study 7547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with 15 micrograms epinephrine
Number of subjects: 30
Study 7547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 30
Study 1781798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (0.02 mg/kg/h followed by 0.03 mg/kg/h after 24 hours)
Number of subjects: 15
Study 1781798 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 15
Study 6589735 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdental brushes
Number of subjects: 9
Study 6589735 — intervention group
Group type: COMPARATOR
Intervention: Waxed dental floss
Number of subjects: 9
Study 31318613 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf raises every 10 min during 3 h of sitting (CALF)
Number of subjects: 20
Study 31318613 — intervention group
Group type: COMPARATOR
Intervention: Control group with no calf raises during 3 h of sitting (CON)
Number of subjects: 20
Study 28220291 — intervention group
Group type: EXPERIMENTAL
Intervention: Gufoni maneuver (n = 70)
Number of subjects: 209
Study 28220291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid oscillation (n = 67)
Number of subjects: 209
Study 28220291 — intervention group
Group type: COMPARATOR
Intervention: Sham maneuver (n = 72)
Number of subjects: 209
Study 26166528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular protrusion of Class III
Number of subjects: 180
Study 26166528 — intervention group
Group type: COMPARATOR
Intervention: Maxillary retrusion of Class III
Number of subjects: 180
Study 26166528 — intervention group
Group type: COMPARATOR
Intervention: Class I
Number of subjects: 180
Study 26166528 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular retrusion of Class III
Number of subjects: 180
Study 25119953 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Literacy prototype
Number of subjects: 1003
Study 25119953 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Facts
Number of subjects: 1003
Study 25119953 — intervention group
Group type: EXPERIMENTAL
Intervention: Column
Number of subjects: 1003
Study 25119953 — intervention group
Group type: COMPARATOR
Intervention: Current standard Med Guides
Number of subjects: 1003
Study 22080629 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chest compression cardiopulmonary resuscitation
Number of subjects: 406
Study 22080629 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation
Number of subjects: 406
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard shoes
Number of subjects: 36
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft sole shoes
Number of subjects: 36
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-collar shoes
Number of subjects: 36
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet surface
Number of subjects: 36
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects
Number of subjects: 36
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects
Number of subjects: 36
Study 19359178 — intervention group
Group type: COMPARATOR
Intervention: Control surface
Number of subjects: 36
Study 19359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular surface
Number of subjects: 36
Study 17530961 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 linear position transducer (1‐LPT)
Number of subjects: 9
Study 17530961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 linear position transducers and a force plate (2‐LPT + FP)
Number of subjects: 9
Study 17530961 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 linear position transducer and a force plate (1‐LPT + FP)
Number of subjects: 9
Study 15329504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil alone or in combination with aprindine
Number of subjects: 38
Study 15329504 — intervention group
Group type: COMPARATOR
Intervention: Electrical conversion with conventional antiarrhythmic drugs other than bepridil and aprindine
Number of subjects: 38
Study 15329504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil treatment
Number of subjects: 38
Study 15329504 — intervention group
Group type: COMPARATOR
Intervention: Electrical conversion
Number of subjects: 38
Study 11601567 — intervention group
Group type: EXPERIMENTAL
Intervention: AND-HB (300 mg androstenediol, 480 mg saw palmetto, 450 mg indole-3-carbinol, 300 mg chrysin, 1500 mg gamma-linolenic acid, 1350 mg Tribulus terrestris per day)
Number of subjects: 55
Study 11601567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11601567 — intervention group
Group type: EXPERIMENTAL
Intervention: AND-HB
Number of subjects: 55
Study 9685822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg, twice daily for a week)
Number of subjects: 26
Study 9685822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for a week)
Number of subjects: 26
Study 9685822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 26
Study 9685822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8027274 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) co-treatment with human menopausal gonadotrophins (HMG) and human chorionic gonadotrophin (HCG)
Number of subjects: 32
Study 8027274 — intervention group
Group type: COMPARATOR
Intervention: HMG/HCG alone
Number of subjects: 32
Study 2681819 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and visual feedback system
Number of subjects: 22
Study 2681819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 22
Study 797678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic central nervous system (CNS) therapy
Number of subjects: 50
Study 797678 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic CNS therapy (Control)
Number of subjects: 50
Study 797678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic CNS therapy
Number of subjects: 50
Study 29984550 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP + CT
Number of subjects: 127
Study 29984550 — intervention group
Group type: COMPARATOR
Intervention: ERP
Number of subjects: 127